[WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled: “Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.](https://wbbsec.com/press-releases/wbb-securities-invites-you-to-attend-the-upcoming-demy-colton-virtual-salon-titled-seven-years-after-fda-approval-what-have-we-learned-about-cell-and-gene-therapies/)
[WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled: “Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.](https://wbbsec.com/press-releases/wbb-securities-invites-you-to-attend-the-upcoming-demy-colton-virtual-salon-titled-seven-years-after-fda-approval-what-have-we-learned-about-cell-and-gene-therapies/)
In: Opinions & Features

12.8.2022 | STAT First Opinion

In a STAT First Opinion commentary on December 8, 2022, Another Theranos crime: Loss of trust in real-time diagnostics (statnews.com), Dr. Steve Brozak explains that for Theranos, “neither lives saved nor health care improvement mattered. Instead, it was the allure of a Facebook-type of return.” 

He also explains the consequence of the fallout from the Theranos narrative, “instead of leading the way in the Covid-19 pandemic, the diagnostic industry was an incidental participant, handcuffed by government caution and investor hesitancy.”  

He advises that “It’s time to start working on the forever task of repairing that.”

To read the entire article on STAT First Opinion, Please click here…